To the full analysis
Buyback calculator for Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International stock: key metrics
KNSAKiniksa Pharmaceuticals International had an operating margin of 11.4% and a return on invested capital (ROIC) of 27.9% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2016 | no data | no data | no data |
| 2017 | no data | no data | no data |
| 2018 | no data | no data | no data |
| 2019 | no data | no data | no data |
| 2020 | no data | no data | no data |
| 2021 | 76.4% | −406.4% | −409.7% |
| 2022 | 89.6% | 4.4% | 83.3% |
| 2023 | 79.1% | −9.3% | 5.2% |
| 2024 | 85.6% | −10.8% | −10.2% |
| 2025 | 54.6% | 11.4% | 8.7% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2016 | 93.2% | −35.0% | −42.5% |
| 2017 | 72.3% | no data | −100.0% |
| 2018 | 53.1% | −55.2% | −32.1% |
| 2019 | −71.8% | −53.1% | −63.6% |
| 2020 | −51.7% | −45.7% | −46.2% |
| 2021 | −85.3% | −48.9% | −67.8% |
| 2022 | 46.3% | 8.9% | 39.9% |
| 2023 | 3.2% | −8.7% | 2.7% |
| 2024 | −9.9% | −16.0% | −7.4% |
| 2025 | 10.4% | 27.9% | 7.7% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Oct 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.